Basel, December 15, 2017 - Novartis announced today that Bruno Strigini, CEO Novartis Oncology has decided to retire from Novartis and the industry for personal reasons.
Joseph Jimenez, CEO of Novartis, said: "I'd like to thank Bruno Strigini for his contributions and achievements. He has navigated the business unit through the Gleevec® patent expiration and has led the successful integration of the GSK Oncology Product Portfolio acquired in 2015. I wish him the best for his future."
Bruno Strigini will step back from the Executive Committee of Novartis by December 31, ...
On a muggy Thursday in July, Chankey Kumar awoke early, as usual, in the two-bedroom home he, his wife and their infant son share with his parents, aunt, uncle, and two young cousins. He slipped on a blue collared shirt and dress pants — a formality that is unusual where he lives in a working-class neighborhood on the outskirts of Meerut, India, a city several hours north of New Delhi.
This story represents a specific point in time in Ryan’s journey with ALL.
In early August 2015, just two weeks into his school year, 11-year-old Ryan showed signs of what his parents thought was a typical stomach bug. But what started as a stomachache and an on- again, off-again fever turned into a shocking diagnosis of leukemia – and a battle for Ryan, his family and his healthcare team to gain control over his cancer.
When Ryan became ill, his parents, Jenny and Mike, took him to his primary care doctor for an exam and blood tests. The results showed Ryan had ...